Memorial Sloan Kettering Cancer Center

SOPHiA GENETICS launches MSK-IMPACT® powered with SOPHiA DDM™, enabling global access to Memorial Sloan Kettering Cancer Center's comprehensive genomic profiling. This enhances precision oncology analysis accuracy and efficiency, with a 5-day process from DNA extraction to final report, benefiting from MSK's OncoKB™ knowledge base.

Jazz Pharmaceuticals announces FDA accelerated approval of Ziihera, the first dual HER2-targeted bispecific antibody for HER2+ biliary tract cancer, based on a 52% objective response rate and 14.9-month median duration of response from the HERIZON-BTC-01 trial. Continued approval may depend on results from the ongoing Phase 3 HERIZON-BTC-302 trial.

Jazz Pharmaceuticals announces FDA approval of Ziihera, the first dual HER2-targeted bispecific antibody for HER2+ BTC, based on a 52% objective response rate and 14.9-month median duration of response from the HERIZON-BTC-01 trial.

COTA's study reveals DLBCL patients initiating treatment immediately post-diagnosis may experience worse outcomes compared to those starting later, with shorter median times to next-line therapy and overall survival rates. Presented at the 66th ASH 2024 Annual Meeting, the research also highlights higher ECOG scores and high-risk clinical features in these patients, emphasizing the need for informed future trials and practices.

Developing a precision approach to anesthetic/analgesic immunomodulation in cancer, exploring biomarkers (TMB, FGA) predictive of immunotherapy response and resistance. Analyzing drug effects on survival and recurrence in lung and colon adenocarcinoma patients, correlating drug target receptor gene expression with TMB, FGA, and immune cell types. Suggesting TMB and FGA as predictive biomarkers for anesthetic/analgesic dose effects on cancer patient survival.

David H. Aggen, MD, PhD, discusses the challenge of personalizing frontline treatment for urothelial cancer patients living over 2 years, highlighting the FDA approvals of enfortumab vedotin-ejfv plus pembrolizumab and nivolumab plus cisplatin and gemcitabine. Aggen emphasizes the need for biomarker research to guide treatment selection and mitigate toxicity, noting the potential use of circulating tumor DNA (ctDNA) to tailor therapy.

FDA grants accelerated approval to Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer, based on 52% objective response rate and 14.9 months median duration of response. Continued approval contingent on confirmatory trial results.

Real-world data on teclistamab use in RRMM show decreasing hospitalization days, CRS incidence at 41%, and potential for less frequent dosing without affecting outcomes. Outpatient step-up dosing is feasible with proper patient selection and education.

Molecular testing shapes treatment decisions in advanced pancreatic cancer, with RAS inhibitors potentially increasing genetic testing importance. Bekaii-Saab discusses chemotherapy regimen selection, emphasizing molecular testing's role and targeted therapies' potential. Triplet regimens like NALIRIFOX and FOLFIRINOX are favored over doublets, though gemcitabine plus nab-paclitaxel shows comparable efficacy. NAPOLI 3 data suggests NALIRIFOX's superiority, though toxicity considerations remain. Germline and somatic tumor profiling guide treatment, especially for RAS mutations and other targeted strategies.

Urothelial carcinoma treatment has evolved with FDA approvals of enfortumab vedotin-ejfv + pembrolizumab and nivolumab + cisplatin/gemcitabine. Personalized therapy is crucial as patients now live longer, but toxicity remains a challenge. Circulating tumor DNA (ctDNA) may help tailor treatment, and ongoing research explores combinations like sacituzumab govitecan + enfortumab vedotin. The landscape is rapidly changing, emphasizing the need for more biomarker research to guide treatment selection.